{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barbulescu A"],"funding":["Bristol Myers Squibb","Swedish Research Council","AbbVie"],"pagination":["3952-3962"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9536798"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["61(10)"],"pubmed_abstract":["Objectives
To describe the use of baricitinib and tofacitinib by Swedish RA patients and to compare their effectiveness with that of biologic DMARDs (bDMARDs).Methods
RA patients who initiated baricitinib (n = 1420), tofacitinib (n = 316), abatacept (n = 1050), IL-6 inhibitors (IL-6is; n = 849), rituximab (n = 1101) or TNF inhibitors (TNFis; n = 6036) between January 2017 and November 2019 were followed for a minimum of 1 year using data from several linked Swedish national registers. Proportions reaching a good EULAR 28-joint DAS (DAS28) response, HAQ Disability Index (HAQ-DI) improvement >0.2 units and Clinical Disease Activity Index (CDAI) remission were compared at 1 year, imputing discontinued treatments as 'non-response'. Additionally, we compared drug retention and c"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data."],"pmcid":["PMC9536798"],"funding_grant_id":["2016-01355","2019-01292"],"pubmed_authors":["Chatzidionysiou K","Askling J","Barbulescu A","Turesson C","Lindstrom U","Frisell T","Forsblad-d'Elia H","Kastbom A"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.","description":"Objectives
To describe the use of baricitinib and tofacitinib by Swedish RA patients and to compare their effectiveness with that of biologic DMARDs (bDMARDs).Methods
RA patients who initiated baricitinib (n = 1420), tofacitinib (n = 316), abatacept (n = 1050), IL-6 inhibitors (IL-6is; n = 849), rituximab (n = 1101) or TNF inhibitors (TNFis; n = 6036) between January 2017 and November 2019 were followed for a minimum of 1 year using data from several linked Swedish national registers. Proportions reaching a good EULAR 28-joint DAS (DAS28) response, HAQ Disability Index (HAQ-DI) improvement >0.2 units and Clinical Disease Activity Index (CDAI) remission were compared at 1 year, imputing discontinued treatments as 'non-response'. Additionally, we compared drug retention and c","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-25T17:35:52.403Z","creation":"2024-11-12T03:59:20.842Z"},"accession":"S-EPMC9536798","cross_references":{"pubmed":["35134119"],"doi":["10.1093/rheumatology/keac068"]}}